Stage, survival and delays in lung, colorectal, prostate and ovarian cancer: comparison between diagnostic routes

By Neal Richard D   Allgar Victoria L   Ali Nasreen   Leese Brenda   Heywood Phil   Proctor Gill   Evans Joyce  

British Journal of General Practice, Vol. 57, Iss. 536, 2007-03 ,pp. : 212-219

Royal College of General Practitioners

Access to resources Recommend Favorite

Validation of Self-Report of Chest X-Ray Exam at a Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Center

By  

Reviews on Recent Clinical Trials, Vol. 10, Iss. 3, 2015-01 ,pp. : 194-199

Bentham Science Publishers

Access to resources Recommend Favorite

Changes in and Impact of the Death Review Process in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial

By  

Reviews on Recent Clinical Trials, Vol. 10, Iss. 3, 2015-01 ,pp. : 206-211

Bentham Science Publishers

Access to resources Recommend Favorite

Influence of MDM2 SNP309 and SNP285 status on the risk of cancer in the breast, prostate, lung and colon

By  

INTERNATIONAL JOURNAL OF CANCER, Vol. 137, Iss. 1, 2015-07 ,pp. : 96-103

John Wiley & Sons Inc

Access to resources Recommend Favorite

Willingness to pay to prevent chemotherapy induced nausea and vomiting among patients with breast, lung, or colorectal cancer

By Miller Paul J. E.   Balu Sanjeev   Buchner Deborah   Walker Mark S.   Stepanski Edward J.   Schwartzberg Lee S.  

Journal of Medical Economics, Vol. 16, Iss. 10, 2013-10 ,pp. : 1179-1189

Informa Healthcare

Access to resources Recommend Favorite